High profile cyber thefts have recently brought trade secret protection to the mainstream. Congress is currently considering several pieces of legislation that aim to better protect the trade secrets of U.S. businesses. Finnegan partner John M. Williamson discusses the value of trade secrets, the current landscape of trade secret law, and how proposed trade secret legislation could impact U.S. companies moving forward.

High profile cyber thefts have recently brought trade secret protection to the mainstream. Congress is currently considering several pieces of legislation that aim to better protect the trade secrets of U.S. businesses.

Technological advancements that were once considered sci-fi have become commonplace in everyday life. Smart home devices, robots and drones are examples of technologies that are being adopted by both enterprise and consumers. As is often the case, the expanse of innovation can outpace a developer's ability to appropriately protect their intellectual property, leaving inventors vulnerable.

The Biologics Price Competition and Innovation Act was signed into existence in 2010 to help drive down the price of biologics by encouraging the development of competitive biosimilars. Since then, there have been many questions around the BPCIA and the provisions for asserting and challenging relevant patents. One example is the recent Federal Circuit case, Sandoz v. Amgen, which could have significant implications for future patent challenges associated with biosimilars. Finnegan attorneys Sanya Sukduang and Jonathan R. Davies, Ph.D. discuss the current legal and regulatory landscape for biosimilars.

The Biologics Price Competition and Innovation Act was signed into existence in 2010 to help drive down the price of biologics by encouraging the development of competitive biosimilars. Since then, there have been many questions around the BPCIA and the provisions for asserting and challenging relevant patents.

Finnegan Partner and European Patent Attorney Hazel Ford discusses the state of stem cell patenting in Europe.

On December 16, 2014, the USPTO issued guidance on subject matter eligibility of claims under Section 101 in view of the Supreme Court’s decisions in Alice, Myriad and Mayo. Finnegan attorneys Leslie McDonell and Linda Thayer explain these guidelines and discuss the potential impact they will have on patent claims.

On December 16, 2014, the USPTO issued guidance on subject matter eligibility of claims under Section 101 in view of the Supreme Court's decisions in Alice, Myriad and Mayo

In part four of our Federal Circuit podcast series, Finnegan attorney Michael Jakes discusses the trend of the Supreme Court overturning Federal Circuit cases

In part four of our Federal Circuit podcast series, Finnegan attorney Michael Jakes discusses the trend of the Supreme Court overturning Federal Circuit cases.